Literature DB >> 12928383

Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.

Robbie B Mailliard1, Young-Ik Son, Richard Redlinger, Patrick T Coates, Adam Giermasz, Penelope A Morel, Walter J Storkus, Pawel Kalinski.   

Abstract

Early stages of viral infections are associated with local recruitment and activation of dendritic cells (DC) and NK cells. Although activated DC and NK cells are known to support each other's functions, it is less clear whether their local interaction in infected tissues can modulate the subsequent ability of migrating DC to induce T cell responses in draining lymph nodes. In this study, we report that NK cells are capable of inducing stable type 1-polarized "effector/memory" DC (DC1) that act as carriers of NK cell-derived helper signals for the development of type 1 immune responses. NK cell-induced DC1 show a strongly elevated ability to produce IL-12p70 after subsequent CD40 ligand stimulation. NK-induced DC1 prime naive CD4+ Th cells for high levels of IFN-gamma, but low IL-4 production, and demonstrate a strongly enhanced ability to induce Ag-specific CD8+ T cell responses. Resting NK cells display stringent activation requirements to perform this novel, DC-mediated, "helper" function. Although their interaction with K562 cells results in effective target cell killing, the induction of DC1 requires a second NK cell-activating signal. Such costimulatory signal can be provided by type I IFNs, common mediators of antiviral responses. Therefore, in addition to their cytolytic function, NK cells also have immunoregulatory activity, induced under more stringent conditions. The currently demonstrated helper activity of NK cells may support the development of Th1- and CTL-dominated type 1 immunity against intracellular pathogens and may have implications for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928383     DOI: 10.4049/jimmunol.171.5.2366

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  132 in total

Review 1.  Induction of RNA interference in dendritic cells.

Authors:  Mu Li; Hua Qian; Thomas E Ichim; Wei-Wen Ge; Igor A Popov; Katarzyna Rycerz; John Neu; David White; Robert Zhong; Wei-Ping Min
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

3.  Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

Authors:  Thanh Nhan Nguyen Pham; Cheol Yi Hong; Jung-Joon Min; Joon-Haeng Rhee; Truc Anh Thi Nguyen; Byoung Chul Park; Deok-Hwan Yang; Young-Kyu Park; Hyeong-Rok Kim; Ik-Joo Chung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Exp Mol Med       Date:  2010-06-30       Impact factor: 8.718

4.  Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs.

Authors:  Guido Ferlazzo; Maggi Pack; Dolca Thomas; Casper Paludan; Dorothee Schmid; Till Strowig; Gwenola Bougras; William A Muller; Lorenzo Moretta; Christian Münz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-09       Impact factor: 11.205

5.  Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection.

Authors:  Eric T T L Tjwa; Gertine W van Oord; Paula J Biesta; Andre Boonstra; Harry L A Janssen; Andrea M Woltman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

6.  Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation.

Authors:  Antonio Perez-Martinez; Rekha Iyengar; Kwan Gan; Thirachit Chotsampancharoen; Barbara Rooney; Marti Holladay; Manuel Ramírez; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

7.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

8.  Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin.

Authors:  Jessica J O'Konek; Elena Ambrosino; Anja C Bloom; Lise Pasquet; Chandirasegaran Massilamany; Zheng Xia; Masaki Terabe; Jay A Berzofsky
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

9.  Dendritic cells stimulated with Actinobacillus actinomycetemcomitans elicit rapid gamma interferon responses by natural killer cells.

Authors:  T Kikuchi; C L Hahn; S Tanaka; S E Barbour; H A Schenkein; J G Tew
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 10.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.